PE-22-28 Reconstitution Calculator

PE-22-28 is a synthetic seven-amino-acid peptide taken from a piece of spadin — a natural fragment of the sortilin protein — and its job is to block the TREK-1 potassium channel in the brain. That mechanism is the whole point: mice lacking TREK-1 are resistant to depression, so inhibiting the channel produces fast antidepressant-like effects in rodent tests, and PE-22-28 does it far more potently than spadin itself while also boosting hippocampal neurogenesis. It's a genuinely novel approach compared with SSRIs, ketamine, or psychedelics — but so far the evidence is entirely preclinical.

It comes as a lyophilized powder, so add bacteriostatic water down the vial wall, swirl gently, and don't shake. As an illustrative example, an 8 mg vial with 6 mL of bacteriostatic water gives 1.33 mg/mL, so a 400 mcg dose would be 0.3 mL — 30 units on a U-100 insulin syringe. Since there are no human dosing studies, treat any figure like this as extrapolated from animal work rather than an established amount.

In the research, PE-22-28 and its parent spadin were given by injection, and that's the form this calculator covers — the reconstituted lyophilized powder. It's also sold as a pre-made nasal spray, which is dosed per spray and isn't something you reconstitute yourself; nasal delivery is often chosen for peptides to ease brain access and skip injections. Which route makes sense is a separate question from the mixing math, and neither has validated human dosing behind it.

All three get lumped together as "mood and brain" peptides, but they act through completely different targets. PE-22-28 blocks the TREK-1 potassium channel as an antidepressant strategy, Selank is a tuftsin-derived anxiolytic that modulates GABA (calming rather than mood-lifting), and Dihexa works on the HGF/c-Met pathway aimed at synapse formation and cognition. They aren't interchangeable, so if you're comparing them it's worth reading each on its own terms rather than treating them as versions of one thing.

Because PE-22-28 has only been studied in animals, its side-effect profile in humans is essentially unknown, and no completed clinical trials establish that it's safe or effective. It's important to be clear that this is an early-stage research compound, not a treatment for depression — depression is a serious medical condition that warrants care from a qualified professional, and PE-22-28 is not a substitute for that. It isn't FDA-approved, and blocking a channel involved in mood, pain, and other functions simply hasn't been characterized for safety in people.